Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



63% Implosion: The Epic Collapse of Provectus Biopharmaceuticals, Inc

Provectus Biopharmaceuticals (NYSEMKT: PVCT  ) resumed trading today, but shareholders probably wished it was still frozen from last Friday. Shares collapsed a startling 63% on news that the FDA would not grant a breakthrough designation to Provectus' melanoma drug PV-10.

In this episode of Market Checkup, The Motley Fool's health-care-focused investing show, analysts David Williamson and Michael Douglass discuss the controversy surrounding Provectus, the increasing competition for its mid-stage drug, and whthere the stock is a bad news buy.

Watch and find out.


Will this stock be your next multibagger?
Give us five minutes and we'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks one stock with amazing potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303%! You don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.


Read/Post Comments (4) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On May 28, 2014, at 2:19 AM, Gaugamela wrote:

    You guys need to research things more thoroughly before you make a videos. The difference of opinion on PV-10 is that the drug's intent is to destroy tumors. The FDA wanted information on symptom control for things like bleeding and pain. The Phase 2 trial wasn't set up to obtain that type of information because the drug is meant to eliminate tumors, not assist with symptoms.

    Provectus felt that eliminating a tumor would count towards eliminating bleeding and pain. Since the FDA has their heads firmly planted up their rear ends, they disagreed.

  • Report this Comment On May 28, 2014, at 1:09 PM, goodswallow wrote:

    I agree with the above comment about your research.

    I believe there is more to this than simply the lack of acceptance about PV-10. I have an idea from other research that there is financial malfeasance by the company - having read about their research in a barn in a field outside of Knoxville, Tn. Furthermore, you can't even contact them - no number is listed or address. Sounds fishy to me. I sold my shares at a big loss.

  • Report this Comment On May 30, 2014, at 1:41 AM, Gaugamela wrote:

    @goodswallow....I know that it's really tough to find their number and address on their web site. It's really, really counterintuitive, but the info is actually under the "Contact Us" section of their web site. I know, mind blowing...They need to be more specific, don't they?

    For the record, I have a friend who has actually called and spoken to the CEO. Why not actually make the attempt before posting lies?

  • Report this Comment On May 30, 2014, at 12:17 PM, rdtshaw wrote:

    @goodswallow I'm sorry but that information is completely incorrect. The contact info is on the website, PVCT has been at this for quite some time. I have a friend that is a researcher at Provectus and she was *completely giddy* about the most recent results with the trials of the new medication. She said she couldn't go into detail(beyond what is in the media), at the time, but she was genuinely excited. I don't begin to understand what goes into getting FDA approval, but if you speak with anyone in the pharmaceutical business, their eyes will immediately roll when the FDA is brought up. Completely dumping everything on such a low price stock invested in a company that is doing some amazing things seems a bit short sighted IMO. PVCT is one I'm keeping an eye on. For both financial and health reasons, (mostly the latter), I hope they are successful.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2973323, ~/Articles/ArticleHandler.aspx, 8/28/2015 6:42:26 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

David Williamson

The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...

Today's Market

updated Moments ago Sponsored by:
DOW 16,643.01 -11.76 -0.07%
S&P 500 1,988.87 1.21 0.06%
NASD 4,828.33 15.62 0.32%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/28/2015 4:00 PM
PVCT $0.40 Down -0.01 -1.34%
Provectus Pharmace… CAPS Rating: *
AMGN $155.89 Up +0.17 +0.11%
Amgen, Inc. CAPS Rating: ****
BMY $60.61 Down -0.21 -0.35%
Bristol-Myers Squi… CAPS Rating: ****